About Covance (NYSE:CVD)
Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorBiotechnology & Medical Research - NEC
Trailing P/E Ratio33.0462962962963
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity12.64%
Return on Assets8.17%
Covance (NYSE:CVD) Frequently Asked Questions
What is Covance's stock symbol?
Covance trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVD."
How were Covance's earnings last quarter?
Covance Inc. (NYSE:CVD) announced its quarterly earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 EPS for the quarter, hitting the consensus estimate of $0.97. The healthcare company had revenue of $634 million for the quarter, compared to analysts' expectations of $631.30 million. Covance had a net margin of 7.70% and a return on equity of 12.64%. View Covance's Earnings History.
Who are some of Covance's key competitors?
Some companies that are related to Covance include Qiagen (QGEN), Anacor Pharmaceuticals (ANAC), Shire Viropharma (VPHM), WuXi PharmaTech (Cayman) (WX), Genus (GNS), Albany Molecular Research (AMRI), Prosensa (RNA), Puretech Health (PRTC), Protalix Biotherapeutics (PLX), Cellular Dynamics International (ICEL), Horizon Discovery Group (HZD), Palatin Technologies (PTN), Silence Therapeutics (SLN), Bioventix (BVXP), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Matinas BioPharma (MTNB) and Navidea Biopharmaceuticals (NAVB).
Has Covance been receiving favorable news coverage?
Headlines about CVD stock have trended positive on Monday, Accern reports. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Covance earned a media sentiment score of 0.30 on Accern's scale. They also assigned media stories about the healthcare company an impact score of 46.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Covance?
Shares of CVD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covance's stock price today?
One share of CVD stock can currently be purchased for approximately $107.07.
How big of a company is Covance?
Covance has a market capitalization of $6.06 billion.
How can I contact Covance?
Covance's mailing address is 210 Carnegie Ctr, PRINCETON, NJ 08540-6233, United States. The healthcare company can be reached via phone at +1-609-4524440.
MarketBeat Community Rating for Covance (CVD)MarketBeat's community ratings are surveys of what our community members think about Covance and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Covance (NYSE:CVD) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Covance (NYSE:CVD) Earnings History and Estimates Chart
Covance (NYSE CVD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/4/2015||Q414||$0.97||$0.97||$631.30 million||$634.00 million||View||N/A|
|11/3/2014||Q314||$0.98||$0.98||$651.00 million||$627.00 million||View||N/A|
|7/29/2014||Q214||$0.93||$0.95||$639.80 million||$687.10 million||View||N/A|
|5/1/2014||Q114||$0.90||$0.90||$632.01 million||$620.10 million||View||N/A|
|2/4/2014||Q413||$0.84||$0.87||$613.80 million||$623.00 million||View||N/A|
|10/29/2013||Q3 2013||$0.80||$0.83||$595.55 million||$647.05 million||View||N/A|
|7/30/2013||Q2 2013||$0.77||$0.78||$586.12 million||$644.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.72||$0.75||$569.34 million||$580.20 million||View||N/A|
|1/24/2013||Q4 2012||$0.71||$0.73||$548.84 million||$562.20 million||View||N/A|
|11/5/2012||Q312||$0.67||$0.72||$546.52 million||$597.66 million||View||N/A|
Covance (NYSE:CVD) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Covance (NYSE:CVD)
No dividend announcements for this company have been tracked by MarketBeat.com
Covance (NYSE CVD) Insider Trading and Institutional Ownership History
Covance (NYSE CVD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/22/2014||Brian H Nutt||Insider||Sell||1,127||$103.51||$116,655.77|| |
|12/18/2014||Joseph L Herring||CEO||Sell||32,692||$103.02||$3,367,929.84|| |
|12/10/2014||John E Watson||VP||Sell||15,200||$102.94||$1,564,688.00|| |
|9/9/2014||Joseph L Herring||CEO||Sell||32,200||$85.13||$2,741,186.00|| |
|2/20/2014||James Lovett||VP||Sell||14,955||$102.47||$1,532,438.85||45,981|| |
|2/10/2014||Brian Nutt||Insider||Sell||1,808||$100.12||$181,016.96||1,099|| |
|2/10/2014||Richard Cimino||EVP||Sell||13,000||$99.10||$1,288,300.00||55,462|| |
|2/10/2014||Sandra Helton||Director||Sell||2,800||$99.03||$277,284.00||15,688|| |
|9/20/2013||Richard Cimino||EVP||Sell||16,000||$84.86||$1,357,760.00||59,437|| |
|9/5/2013||Sandra L Helton||Director||Sell||3,000||$81.92||$245,760.00|| |
|9/5/2013||William E Klitgaard||VP||Sell||25,323||$81.44||$2,062,305.12|| |
|8/21/2013||Deborah Keller||EVP||Sell||15,900||$83.12||$1,321,608.00||53,029|| |
|8/16/2013||Robert Barchi||Director||Sell||13,667||$82.78||$1,131,354.26||4,740|| |
|8/2/2013||Gary Costley||Director||Sell||7,467||$82.77||$618,043.59||4,540|| |
|8/2/2013||Joseph Herring||CEO||Sell||100,000||$82.54||$8,254,000.00||229,704|| |
|6/27/2013||Joseph L Herring||CEO||Sell||13,259||$77.00||$1,020,943.00|| |
|6/19/2013||Joseph L Herring||CEO||Sell||22,391||$78.03||$1,747,169.73|| |
|5/15/2013||James W Lovett||VP||Sell||10,259||$77.00||$789,943.00|| |
Covance (NYSE CVD) News Headlines
Covance (NYSE:CVD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Covance (NYSE:CVD) Income Statement, Balance Sheet and Cash Flow Statement
Covance (NYSE CVD) Stock Chart for Monday, March, 19, 2018